VORSCHAU
Frühere Meldungen
PRESSETERMINE
AKTUELLES PRESSEFOTO
IR Nachrichten
05.05.2024 09:00
Small- & MicroCap Investment
05.05.2024 08:30
Small- & MicroCap Investment
05.05.2024 08:00
Small- & MicroCap Investment
EUROPA NACHRICHTEN
ADHOC
Fr, 07.08.2020 07:30
pta20200807011
Business news for the stock market
Medigene AG: Medigene provides Q2 update and 6M report 2020
Conference call on 7 August 2020 at 2pm CET (Frankfurt) / 8am EDT (New York)
Martinsried/ Munich (pta011/07.08.2020/07:30) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today published its 6-Months Report 2020 with an overview on its business performance and financial results. The full version of the report can be downloaded here: https://www.medigene.com/investors-media/reports-presentations/ Prof. Dolores Schendel, CEO/CSO at Medigene: "We are in the fortunate position to report that our research and development projects have continued to progress uninterrupted over the past six months. With the start of our second clinical trial with T cell receptor (TCR) immunotherapy MDG1021 at the Leiden University Medical Center (LUMC), we have reached another milestone. Despite the special circumstances caused by the coronavirus pandemic, the trial site in the Netherlands is working intensely at screening and recruiting patients. Recruitment for our clinical Phase I/II trial with MDG1011 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients is on track. We have also made further progress in our strategic collaboration and discovery agreement with our Asian partner Cytovant Sciences HK Ltd. (Roivant/Cytovant). Within this collaboration, Medigene started research and development work for the first target antigen chosen by Roivant/Cytovant for a TCR immunotherapy. We look forward to an exciting second half of 2020 and thank our shareholders for their confidence in us."
Business review Q2 2020:
Company outlook:
Financial development and guidance:
Conference call:
Date of telephone conference: Friday, 7 August 2020
Register online/ Dial in number:
--- end of press release ---
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list. (Ende)
FOTODIENST
PRESSETEXT.TV
Walter Oblin sieht Post auf Wachstumskurs 18.04.2023 ETARGET
FOCUSTHEMA
SPECIALS
Werbung
middleAdvertising
|